Morgan Stanley Prelude Therapeutics Inc Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Morgan Stanley holds 302,779 shares of PRLD stock, worth $302,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares

302,779

Previous 365,159 17.08%

Holding current value

$302,779

Previous $463,000 49.68%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.64 - $1.39 $39,923 - $86,708	-62,380 Reduced 17.08%	302,779 $233,000
Q4 2024 Feb 14, 2025	BUY	$0.8 - $2.04 $33,176 - $84,598	41,470 Added 12.81%	365,159 $463,000
Q3 2024 May 14, 2025	BUY	$2.07 - $6.37 $75,213 - $231,453	36,335 Added 12.64%	323,689 $670,000
Q3 2024 Nov 14, 2024	BUY	$2.07 - $6.37 $75,213 - $231,453	36,335 Added 12.64%	323,689 $670,000
Q2 2024 May 14, 2025	SELL	$3.32 - $5.63 $258,312 - $438,042	-77,805 Reduced 21.31%	287,354 $1.09 Million
Q2 2024 Oct 17, 2024	SELL	$3.32 - $5.63 $29,385 - $49,831	-8,851 Reduced 2.99%	287,354 $1.09 Million
Q2 2024 Aug 14, 2024	SELL	$3.32 - $5.63 $29,385 - $49,831	-8,851 Reduced 2.99%	287,354 $1.09 Million
Q1 2024 Oct 17, 2024	BUY	$2.68 - $4.84 $23,720 - $42,838	8,851 Added 3.08%	296,205 $1.4 Million
Q1 2024 Aug 16, 2024	SELL	$2.68 - $4.84 $6,943 - $12,540	-2,591 Reduced 0.87%	296,205 $1.4 Million
Q1 2024 May 15, 2024	SELL	$2.68 - $4.84 $6,943 - $12,540	-2,591 Reduced 0.87%	296,205 $1.4 Million
Q4 2023 Aug 16, 2024	BUY	$1.69 - $4.37 $19,336 - $50,001	11,442 Added 3.98%	298,796 $1.28 Million
Q4 2023 Feb 13, 2024	BUY	$1.69 - $4.37 $91,810 - $237,404	54,326 Added 22.22%	298,796 $1.28 Million
Q3 2023 Nov 15, 2023	BUY	$2.74 - $4.79 $134,654 - $235,399	49,144 Added 25.16%	244,470 $755,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $238,804 - $435,751	53,664 Added 37.88%	195,326 $878,000
Q1 2023 May 15, 2023	BUY	$4.58 - $7.34 $236,845 - $379,573	51,713 Added 57.49%	141,662 $807,000
Q4 2022 Feb 14, 2023	SELL	$4.61 - $8.5 $404,937 - $746,631	-87,839 Reduced 49.41%	89,949 $543,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $1.52 Million - $2.67 Million	-303,000 Reduced 63.02%	177,788 $1.18 Million
Q2 2022 Oct 27, 2022	SELL	$4.0 - $7.55 $262,748 - $495,936	-65,687 Reduced 12.02%	480,788 $2.51 Million
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $262,748 - $495,936	-65,687 Reduced 12.02%	480,788 $2.51 Million
Q1 2022 Oct 27, 2022	BUY	$6.9 - $13.22 $453,240 - $868,382	65,687 Added 13.66%	546,475 $3.77 Million
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $2.06 Million - $3.96 Million	-299,239 Reduced 35.38%	546,475 $3.77 Million
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $1.06 Million - $2.82 Million	88,927 Added 11.75%	845,714 $10.5 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $38.65 $19.5 Million - $29.2 Million	756,787 New	756,787 $23.7 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

28.3M

Call Options Held

23.9K

Put Options Held

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $36.4M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account